The effectiveness of oxygen delivery through high flow nasal cannula (HFNC) with different temperatures in improving the clinical symptoms of COVID-19 patients

Evaluation of the effect of using high flow oxygen delivery through a nasal cannula (HFNC) with different temperatures in COVID-19 patients referred to Masih Daneshvari Hospital

The present study is a clinical trial with three intervention groups, with parallel and one-way blind groups, randomized, and with a sample size of 30 patients.

This study is a clinical trial in patients with COVID-19 referred to Masih Daneshvari Hospital in Tehran who have moderate to severe disease and need to be hospitalized and receive respiratory support. Clinical conditions and laboratory tests and analysis of blood gases of patients before and after receiving high flow oxygen through the nasal cannula will be examined. Randomization is done using codes assigned to each patient and using the file number. The primary caregiver is aware of how the groups are assigned. Other blind groups include the researcher analyzing the data.

Inclusion criteria: Evidence of new coronavirus, Saturation˂90, Signature of written consent form Participation in the study, age over 18 years, and patients with moderate or severe COVID-19 in need of hospitalization and respiratory support. Exclusion criteria: Pregnancy and Breastfeeding, decreased patient level of consciousness

Patients with COVID-19 who are require respiratory support are divided into three groups. In the first group, high-flow oxygen delivery through the nasal cannula (HFNC) is regulated at 31 ° C, in the second group at 34 ° C and in the third group at 37 ° C. Also, the flow of oxygen to the patient is the same in all three groups and is 40 liters per minute.

Oxygen saturation, ferritin, interleukin 6, c-reactive protein, Erythrocyte sedimentation rate, alanine aminotransferase, aspartate aminotransferase, D-dimer

With simple randomization and using random number table and individual randomization unit. For randomization, we use a table consisting of random digits 1 to 9. Each digit of this table is repeated the same on average. There is no pattern of recognizable numbers. In this method, each figure is assigned to a treatment group. We start from the first row of the table and move from row to row. For the three treatments, we put the numbers 1 to 3 for treatment A, the numbers 4 to 6 for treatment B, and the numbers 7 to 9 for treatment C. We will continue the above process until the two groups are completed.

To prevent any possible complications, the doctor and clinical caregiver are fully aware of the specificity of the treatment groups. Patients in the study were also not blinded to the type of treatment they were receiving. Researchers responsible for data collection and analysis are not aware of the allocation of different study groups.

There is no more information